...
首页> 外文期刊>Journal of cardiovascular translational research >Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.
【24h】

Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.

机译:接受心脏再同步治疗的非缺血性扩张型心肌病患者的代谢表型评估。

获取原文
获取原文并翻译 | 示例

摘要

Studies of myocardial metabolism have reported that contractile performance at a given myocardial oxygen consumption (MVO2) can be lower when the heart is oxidizing fatty acids rather than glucose or lactate. The objective of this study is to assess the prognostic value of myocardial metabolic phenotypes in identifying non-responders among non-ischemic dilated cardiomyopathy (NIDCM) patients undergoing cardiac resynchronization therapy (CRT). Arterial and coronary sinus plasma concentrations of oxygen, glucose, lactate, pyruvate, free fatty acids (FFA), and 22 amino acids were obtained from 19 male and 2 female patients (mean age 56 +/- 16) with NIDCM undergoing CRT. Metabolite fluxes/MVO2 and extraction fractions were calculated. Flux balance analysis (FBA) was performed with MetaFluxNet 1.8 on a metabolic network of the cardiac mitochondria (189 reactions, 230 metabolites) reconstructed from mitochondrial proteomic data (615 proteins) from human heart tissue. Non-responders based on left ventricular ejection fraction (LVEF) demonstrated a greater mean FFA extraction fraction (35% +/- 17%) than responders [18 +/- 10%, p = 0.0098, area under the estimated ROC curve (AUC) was 0.8238, S.E. 0.1115]. Calculated adenosine triphosphate (ATP)/MVO2 using FBA correlated with change in New York Heart Association (NYHA) class (rho = 0.63, p = 0.0298; AUC = 0.8381, S.E. 0.1316). Non-responders based on both LVEF and NYHA demonstrated a greater mean FFA uptake/MVO2 (0.115 +/- 0.112) than responders (0.034 +/- 0.030, p = 0.0171; AUC = 0.8593, S.E. 0.0965). Myocardial FFA flux and calculated maximal ATP synthesis flux using FBA may be helpful as biomarkers in identifying non-responders among NIDCM patients undergoing CRT.
机译:心肌代谢研究表明,当心脏氧化脂肪酸而不是葡萄糖或乳酸时,在给定的心肌耗氧量(MVO2)下的收缩性能可能会降低。这项研究的目的是评估心肌代谢表型在识别接受心脏再同步治疗(CRT)的非缺血性扩张型心肌病(NIDCM)患者中无反应者中的预后价值。从19例接受CRT的NIDCM的男性和2名女性患者(平均年龄56 +/- 16)获得了动脉和冠状窦血浆中的氧,葡萄糖,乳酸,丙酮酸,游离脂肪酸(FFA)和22种氨基酸的浓度。计算代谢通量/ MVO2和提取率。使用MetaFluxNet 1.8对从人类心脏组织的线粒体蛋白质组数据(615种蛋白质)重建的心脏线粒体的代谢网络(189个反应,230种代谢物)进行通量平衡分析(FBA)。基于左心室射血分数(LVEF)的无反应者表现出比反应者更高的平均FFA提取分数(35%+/- 17%)[18 +/- 10%,p = 0.0098,估计的ROC曲线下面积(AUC) )为0.8238,SE 0.1115]。使用FBA计算的三磷酸腺苷(ATP)/ MVO2与纽约心脏协会(NYHA)类别的变化相关(rho = 0.63,p = 0.0298; AUC = 0.8381,S.E. 0.1316)。基于LVEF和NYHA的无应答者的平均FFA摄取/ MVO2(0.115 +/- 0.112)比应答者(0.034 +/- 0.030,p = 0.0171; AUC = 0.8593,S.E. 0.0965)更高。使用FBA计算出的心肌FFA通量和最大ATP合成通量可能有助于在进行CRT的NIDCM患者中识别无反应的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号